BioPharma Reporter

SEPTEMBER 19, 2023

The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.

Manufacturing 59

Manufacturing Contract Manufacturing Pharma Companies Antibody 59

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. If the Australian pharma company can demonstrate a renewed potential for the drug, Lilly could receive up to $255m in commercial and regulatory milestone payments.

Development 130

Development Antibody Pharma Companies Licensing 130

Pharmaceutical Technology

SEPTEMBER 2, 2022

lenalidomide) + a steroid ± an anti-CD38 antibody. Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. Should CAR-T cells, or antibodies be used first?

Antibody 147

Antibody Sales FDA Approval Production 147

The Pharma Data

DECEMBER 11, 2020

The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccination Vaccine Containment 52

pharmaphorum

NOVEMBER 30, 2020

Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff.

RNA 52

RNA Pharma Companies Antibody Life Science 52

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. AZ/Takeda are meanwhile running phase 2 trials of their MEDI 1342 antibody candidate. Interest in the target has also prompted a flurry of licensing deals.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

JUNE 1, 2022

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5

Gene Therapy 98

Gene Therapy Clinical Development Antibody Gene 98

pharmaphorum

JULY 12, 2021

A diagnostic test to detect long COVID could be available within six to 12 months, following the discovery that patients with the chronic condition have distinctive antibodies in their blood. . Read more in today's Observer [link]. — APPG on Coronavirus (@AppgCoronavirus) July 11, 2021.

Antibody 105

Antibody Pharma Companies Research Vaccination 105

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. Its other clinical stage TAT (BAY 2287411) also uses an antibody and targets mesothelin, an antigen found on the surface of tumour cells.

Antibody 81

Antibody Licensing Licensing Protein 81

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

AUGUST 18, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies. But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Pharma Companies Reagent Scientist 52

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC).

Sales 59

Sales Antibody Drugs Pharma Companies 59

XTalks

FEBRUARY 19, 2021

In the latest round of Amgen’s (NASDAQ: AMGN ) ongoing patent battle against Regeneron (NASDAQ: REGN ) and Sanofi over LDL-lowering PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies, the latter came out with a win last week. However, other companies, including Bristol Myers Squibb and Merck & Co.,

Antibody 85

Antibody Sales Trials Marketing 85

pharmaphorum

APRIL 7, 2021

While the Darzalex revenues are due to fall this year because of Janssen’s interpretation of the agreement between the two companies, there are also other revenue streams. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 91

Antibody Life Science Development Regulation 91

pharmaphorum

AUGUST 21, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses?

Vaccination 105

Vaccination Vaccine Regulation Manufacturing 105

pharmaphorum

MARCH 15, 2022

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias.

Development 111

Development Pharma Companies Clinical Trials Clinical Trials 111

pharmaphorum

SEPTEMBER 21, 2021

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or metastatic cervical cancer.

Antibody 52

Antibody Pharma Companies Trials Drugs 52

pharmaphorum

DECEMBER 21, 2020

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2

Immune Response 59

Immune Response Sales Antibody Pharma Companies 59

pharmaphorum

MAY 12, 2021

Lilly’s head of new therapeutic modalities, Andrew Adams, said that saRNAs are “a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue” The US pharma company has been building a presence in RNA medicines via a series of partnerships, including a $1.2

RNA 76

RNA Protein Drugs Pharma Companies 76

The Pharma Data

JANUARY 24, 2021

.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

pharmaphorum

DECEMBER 1, 2022

Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process. Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability. Utilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods. Who Should Attend?

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

pharmaphorum

FEBRUARY 18, 2021

The body’s immune response to the coronavirus is not limited to antibodies with CD8+ T-cells also playing roll combating infections. ” Pharma companies hope that regulators will accept smaller scale trials of updated vaccines that test immune response, so that shots combating new variants can quickly get to market.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

pharmaphorum

FEBRUARY 28, 2022

million) in the first half of its financial year ended November 30, 2021, slightly down on the same period of 2020 shortly after the company launched. It now counts five of the top 10 pharma companies as customers for its ImmunoINSIGHTS autoantibody profiling platform, and says it expects revenues for the full year to reach around £6 million.

Life Science 52

Life Science Pharma Companies Development Protein 52

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

Drug Discovery World

JULY 3, 2023

Dr Peter Holst, Chief Scientific Officer and Founder, launched the company based on the discovery that the immune system fights cancer the same way it fights viral infections, by deploying the full potential of the humoral (antibody) and cellular (T cell) responses against the invading viruses.

Life Science 52

Life Science Pharma Companies Drugs Marketing 52

XTalks

MARCH 31, 2023

The current investigation builds on a project from 2020 when BMS set out on SpaceX’s CRS-21 to look at ways to improve crystallizing monoclonal antibodies to gain better insights into their structure and crystallization kinetics in microgravity with the overarching goal of improving drug formulation and delivery.

Protein 97

Protein Research Development Manufacturing 97

pharmaphorum

FEBRUARY 14, 2022

In figures, this was represented by 71% of late-stage pipeline revenue being the result of the companies partnering to develop an asset. Due to the increase in funding, more biotechs and smaller scale pharma companies are able to progress assets further into clinical trials.

Production 98

Production Clinical Trials Clinical Trials Sales 98

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. The partnership.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

pharmaphorum

FEBRUARY 14, 2022

It has already completed an 89-subject phase 1 trial, meeting Curevo’s objectives for safety and tolerability and generating an antibody response at one month and one year after a second dose that suggested it has the potential to be as good as Shingrix, according to the company.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. How big pharma tackles rare diseases. It’s a different business model, if you will,” Miquel said. “So So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Vaccination 98